Articles On Immutep (ASX:IMM)

Title Source Codes Date
Market Highlights: Two uttered words that crashed the market, and 5 ASX small caps to watch today

The ASX is set to plunge on Thursday after a crash in New York US Fed unleashed another jumbo 75bp rate hike Fed boss Jerome Powell spooked the markets during his speech   The ASX is poised to plunge on Wednesday, tracking movements in Ne...

Stockhead IMM 1 year ago
ASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon

ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios   Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te...

ShareCafe IMM 1 year ago
Immutep (ASX:IMM) to continue with controlled phase IIB TACTI-003 trial for HNSCC cancer

Immutep (IMM) is given approval by the Independent Data Monitoring Committee (IDMC) to carry on with its planned phase IIb TACTI-003 trialThe IDMC reviewed the initial safety data and concluded that the trial should continue with no modific...

themarketherald.com.au IMM 1 year ago
Market unfazed by CPI data: ASX finishes 0.18% higher

ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios   CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS...

ShareCafe IMM 1 year ago
Australian headline inflation hits highest in 32 years: ASX up 0.12% at noon

ShareCafeAustralian headline inflation hits highest in 32 years: ASX up 0.12% at noon by Lauren Hayes   The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less agg...

ShareCafe IMM 1 year ago
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

Stockhead IMM 1 year ago
Energy and Materials only sectors left lagging: ASX closes 0.28% higher

ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios   In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di...

ShareCafe IMM 1 year ago
Optimism out of the US boosts sentiment: ASX up 0.6% at noon

ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes   Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports...

ShareCafe IMM 1 year ago
Immutep (ASX: IMM) Receives Fast Track Designation from FDA

ShareCafeImmutep (ASX: IMM) Receives Fast Track Designation from FDA   Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company...

ShareCafe IMM 1 year ago
Trading Places: Chinese mining giant backs Tietto Minerals and LGI’s new substantial shareholders

Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas...

Stockhead IMM 1 year ago
ScoPo’s Powerplays: Calmer week for ASX health stocks with some alarming stats about how many people drink instant coffee

During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral...

Stockhead IMM 1 year ago
Energy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher

ShareCafeEnergy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher by Peter Milios   The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 point...

ShareCafe IMM 1 year ago
Second fast-track designation for Australian immunotherapy company

Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab).

BiotechDispatch IMM 1 year ago
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Stockhead IMM 1 year ago
Immutep (ASX:IMM) receives FDA Fast Track designation for NSCLC treatment

Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)The designation — Immutep’s second for the drug — is specifically for efti when used in combination with c...

themarketherald.com.au IMM 1 year ago
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

Stockhead IMM 1 year ago
Why did the Imugene share price implode 31% in September?

The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates. Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September....

Motley Fool IMM 1 year ago
Immutep (ASX:IMM) receives $2.7 million R&D French tax incentive

Immutep (IMM) receives a $2.7 million research and development tax incentive from the French GovernmentThe company received the funds under France’s research tax credit scheme, which sees eligible French companies reimbursed for 30 per cent...

themarketherald.com.au IMM 1 year ago
Immutep provides clinical update on 'efti' and confirms board appointment

Immutep has provided a clinical development update for its first-in-class LAG-3 antigen-presenting cell, activator product candidate, eftilagimod alpha, and announced a major appointment to its board.

BiotechDispatch IMM 1 year ago
Immutep (ASX:IMM) initiates new Phase II trial to evaluate efti in soft tissue sarcoma

Immutep (IMM) signs a material transfer agreement with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, PolandThe partnership will enable an investigator-initiated open label Phase II clinical trial to evaluate...

themarketherald.com.au IMM 1 year ago
ASX Health Stocks: China likes Uscom device, includes it in national emergency guidelines

Uscom’s device is included in China’s emergency guidelines Poland provides grant for Immutep’s Phase 2 trial Medical device company Uscom (ASX:UCM) said that it has been included in the national emergency medicine guidelines for acute hea...

Stockhead IMM 1 year ago
Evening Report: 30 August, 2022

ShareCafeEvening Report: 30 August, 2022 by Paul Sanger   Australian shares have clawed back some of yesterday’s heavy losses despite another slump in global markets over the possibility of more aggressive US and European interest rate hike...

ShareCafe IMM 1 year ago
Immutep (ASX:IMM) granted new Japanese patent

Immutep (IMM) receives a new patent for its immunotherapy treatment for cancer from the Japanese Patent Office The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead acti...

themarketherald.com.au IMM 1 year ago
Lunch Report: 30 August, 2022

ShareCafeLunch Report: 30 August, 2022 by Paul Sanger   The ASX had a solid start to the trading session Tuesday, recovering some of yesterday’s material fall. At noon, the S&P/ASX 200 is 0.48 per cent or 33.50 points higher at 6999.00....

ShareCafe IMM 1 year ago
Stocks of the Hour: 30 August, 2022

ShareCafeStocks of the Hour: 30 August, 2022                    Cobre (ASX:CBE) continues to kick goals, today they announced that their fifth step out drill hole of the ongoing diamond drill programme at the Ngami Copper Project in t...

ShareCafe IMM 1 year ago
Stocks of the Hour: Cobre, Immutep, AD1 Holdings

30 Aug 2022 - A snapshot of the stocks on the move featuring Cobre (ASX:CBE), Immutep (ASX:IMM) and AD1 Holdings (ASX:AD1).

FNN IMM 1 year ago
Earnings preview: Here are the ASX shares reporting today

It is the last day of the busiest week in the August earnings season. Thankfully, you can ease into the weekend with far fewer ASX shares set to report their results today. However, there are still a handful of big names that you might wa...

Motley Fool IMM 1 year ago
Immutep reports new data from phase 2 TACTI-002 trial

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials. The phase 2 TACTI-002 trial is studying the company's LAG-3 Candidate, eftilagimod...

BiotechDispatch IMM 1 year ago
What’s the outlook for Immutep shares in FY23?

Immutep Ltd (ASX: IMM) shares underperformed in FY22 as markets took a turn for the worse. Most of the previous year’s gains were erased. However, the biotech company has caught a bid in July, as healthcare shares continue to strengthen i...

Motley Fool IMM 1 year ago
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Stockhead IMM 1 year ago
What’s the outlook for ASX biotech shares in FY23?

ASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved into higher-quality corners of the market. Here’s a closer look at three noteworthy ASX biotech shares and their outlook for FY23. CSL Ltd...

Motley Fool IMM 1 year ago
Why did the Immutep share price plummet 31% last month?

The Immutep Ltd (ASX: IMM) share price plunged lower in June despite the company announcing seemingly good news to the market. As of the final close of last month, the Immutep share price was 29 cents, 30.95% lower than it was at the end o...

Motley Fool IMM 1 year ago
Here’s how ASX healthcare shares performed in FY22

ASX healthcare shares were a mixed basket this past financial year. After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January. The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around...

Motley Fool IMM 1 year ago
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Stockhead IMM 1 year ago
Evening Report: 6 July, 2022

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

ShareCafe IMM 1 year ago
ASX Health Stocks: ResApp gets FDA nod, while Japan grants Immutep a patent

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

Stockhead IMM 1 year ago
Lunch Report: 6 July, 2022

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

ShareCafe IMM 1 year ago
Immutep (ASX:IMM) granted Japanese patent for IMP761

Immutep (IMM) is granted a Japanese patent for its pre-clinical product candidate, IMP761, valid until 2036 The patent is entitled “Anti-LAG-3 Antibodies” and was granted by the Japanese Patent Office The new patent follows the grant of th...

themarketherald.com.au IMM 1 year ago
Immutep (ASX:IMM) granted Japanese patent for IMP761

06 Jul 2022 - Immutep (ASX:IMM) has been granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases.

FNN IMM 1 year ago
Here’s how ASX 200 healthcare shares performed in June

ASX 200 healthcare shares were defensive in June but finished the month down overall. The benchmark S&P/ASX 200 Health Care Index (ASX: XHJ) was volatile, slipping 3% in June. Nevertheless, there were some names worth mentioning. Let’...

Motley Fool IMM 1 year ago
Own Immutep shares? Here are 3 takeaways from the company’s investor update

Shares of biotech Immutep Ltd (ASX: IMM) have had a hard time this year to date, down 35% since trading resumed in January. At the time of writing, investors are paying 30.5 cents apiece for the Immutep share price. Earlier this month,...

Motley Fool IMM 1 year ago
I think these 2 ETFs are too good to miss in July 2022

Exchange-traded funds (ETFs) can be very useful for investing in shares. ETFs make it to invest passively, get access to different industries or invest in different geographic markets. One of the most popular ETFs is one that gives access...

Motley Fool IMM 1 year ago
What’s driving the Immutep share price in June?

The Immutep Ltd (ASX: IMM) share price has gyrated in recent months, having slumped from a 52-week high of 71 cents back in November to close Friday’s session at 37 cents. Investors pushed the stock to 52-week lows by April this year, wh...

Motley Fool IMM 1 year ago
2022 Has Been Rough for Major Indexes. Here’s Why I’m Not Worried.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. After rallying from t...

Motley Fool IMM 1 year ago
Is The Stock Market Going to Crash Again?

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. With the recent infla...

Motley Fool IMM 1 year ago
ASX shares and inheritances: Survey reveals how Aussies plan to get rich

Men are more likely to invest in ASX shares than women. That’s according to a new YouGov survey commissioned by crypto wealth platform Dacxi. The survey also found that men are almost twice as likely to believe they’ll be rich in their...

Motley Fool IMM 1 year ago
Immutep (ASX:IMM) TACTI-002 data presented at ASCO 2022

ShareCafeImmutep (ASX:IMM) TACTI-002 data presented at ASCO 2022   Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Vice President Strategic Development Christia...

ShareCafe IMM 1 year ago
Australian Broker Call *Extra* Edition – Jun 08, 2022

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

FNArena IMM 1 year ago
Short & Caught: Flight Centre and rate sensitive stocks among ASX most shorted

In Short & Caught, Stockhead recaps the ASX stocks that are the most shorted and have had the greatest increase in short interest right now.   How does shorting work? Shorting works by selling stocks you do not actually own in the hope...

Stockhead IMM 1 year ago
Immutep reports positive overall response rate in lung cancer trial

Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.

BiotechDispatch IMM 1 year ago